Pancreatic cancer

Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer

Targeting angiogenesis has not been successful as a treatment for pancreatic cancer. Studies using monoclonal antibodies or small molecule inhibitors of the VEGFR pathway have failed to demonstrate benefit. Now, a phase II study has shown that sorafenib does not improve the efficacy of gemcitabine plus cisplatin chemotherapy in patients with locally advanced or metastatic pancreatic adenocarcinoma.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Saif, M. W. Anti-angiogenesis therapy in pancreatic carcinoma. JOP 7, 163–173 (2006).

    PubMed  Google Scholar 

  2. 2

    Cascinu, S. et al. Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. Dig. Liver Dis. http://dx.doi.org/10.1016/j.dld.2013.09.020.

  3. 3

    Kindler, H. L. et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28, 3617–3622 (2010).

    CAS  Article  Google Scholar 

  4. 4

    Richly, H. et al. Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV [abstract]. J. Clin. Oncol. 31 (Suppl.), 4035 (2013).

    Google Scholar 

  5. 5

    Kindler, H. L. et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 12, 256–262 (2011).

    CAS  Article  Google Scholar 

  6. 6

    Van Cutsem, E. et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 27, 2231–2237 (2009).

    CAS  Article  Google Scholar 

  7. 7

    Astsaturov, N. J. et al. A randomized phase II and coagulation study of bevacizumab alone or with docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (Suppl.), 4556 (2007).

  8. 8

    Gonçalves, A. et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann. Oncol. 23, 2799–2805 (2012).

    Article  Google Scholar 

  9. 9

    Heinemann, V. et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 24, 3946–3952 (2006).

    CAS  Article  Google Scholar 

  10. 10

    Loges, S., Schmidt, T. & Carmeliet, P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 1, 12–25 (2010).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Muhammad Wasif Saif.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Saif, M. Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer. Nat Rev Gastroenterol Hepatol 11, 8–9 (2014). https://doi.org/10.1038/nrgastro.2013.234

Download citation

Further reading